Author Archives: Marta Figueiredo

Optimal Dose of Tasquinimod Found in First Phase of RRMM Trial

The optimal dosing of tasquinimod, Active Biotech’s experimental oral therapy for adults with relapsed or refractory multiple myeloma, has been determined in a Phase 1b/2a clinical trial. Now, that dose and schedule will be tested, along with the standard oral combination treatment, in the trial’s second phase, the…

Under-the-skin Velcade Found to Work Better in Farydak Triple Combo

Using an under-the-skin formulation of Velcade (bortezomib), in combination with Farydak (panobinostat) and oral dexamethasone, leads to a better safety profile in people with relapsed or refractory (resistant) multiple myeloma than does the therapy’s original into-the-vein version, data show. The triple combination treatment with under-the-skin Velcade also was…

EU Committee Supports Nexpovio for Heavily Treated Myeloma Patients

A combination of Nexpovio (selinexor) and the corticosteroid dexamethasone has been recommended for conditional approval in the European Union to treat adults with relapsed or refractory multiple myeloma who received at least four prior therapies. This includes patients whose disease failed to respond to at least two proteasome inhibitors,…

FDA Approval Sought for Cilta-cel CAR T-cell Therapy

Janssen and Legend Biotech are seeking U.S. approval for their investigational CAR T-cell therapy ciltacabtagene autoleucel  — known as cilta-cel — to treat adults with relapsed or refractory (hard-to-treat) multiple myeloma. A rolling submission of the biologics license application (BLA) for cilta-cel has been started by Janssen…

MMRF Joins Dana-Farber to Advance Research in Smoldering Myeloma

The Multiple Myeloma Research Foundation (MMRF) has joined forces with the Dana Farber Cancer Institute to develop new biomarkers and treatments for people with smoldering multiple myeloma (SMM) — a precursor condition to multiple myeloma. The collaboration will take advantage of MMRF’s data hub CureCloud and at-home genetic test program and Dana Farber’s…

Darzalex Delays Disease Progression After ASCT, Phase 3 Trial Reports

First-line maintenance therapy with Darzalex (daratumumab) significantly delays disease progression or death in adults with multiple myeloma who responded to autologous stem cell transplant (ASCT), according to data from the CASSIOPEIA trial’s second part. These findings, from a pre-planned interim analysis conducted by an independent data monitoring committee, indicate that the Phase 3…